Voruciclib NEW
| Price | $147 | $289 | $455 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-02 |
Product Details
| Product Name: Voruciclib | CAS No.: 1000023-04-0 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2025/05/02 |
Product Introduction
Bioactivity
| Name | Voruciclib |
| Description | Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM) that represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma and effectively blocks CDK9, the transcriptional regulator of MCL-1. |
| In vitro | Voruciclib hydrochloride has Ki values for CDK inhibitor such as CDK9/cyc T2 of 0.626 nM, CDK9/cyc T1 of 1.68 nM, CDK6/cyc D1 of 2.92 nM, CDK4/cyc D1 of 3.96 nM, CDK1/cyc B of 5.4 nM, and CDK1/cyc A of 9.1 nM[1].Voruciclib (0.5-5 μM; 6 hours) displays targeted downregulation of MCL-1 in both ABC and GCB subtypes[1]. |
| In vivo | In ABC subtypes (U2932, RIVA, OCI-LY10), GCB subtypes (SU-DHL-4, NU-DHL-1) xenografted in Female NOD.CB17-Prkdcscid/NCrHsd mice, Combination of 200 mpk Voruciclib hydrochloride and Venetoclax (10 mpk, 1 mpk, 50 mpk, 25 mpk in U2932, RIVA, SU-DHL-4 and NU-DHL-1, respectively) causes increase tumor growth inhibition compared to either drug alone in U2932, RIVA, SU-DHL-4, and NU-DHL-1 models of DLBCL [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 42.5 mg/mL (90.46 mM), Sonication is recommended. |
| Keywords | Voruciclib | stage | orally | multiple | models | MCL-1 | lymphoma | large | Inhibitor | inhibit | DLBCL | diffuse | Cyclin dependent kinase | clinical | CDK9/CycT2 | CDK9/CycT1 | CDK9/cyc T2 | CDK9 | CDK6/cycD1 | CDK4/Cyc D1 | CDK1/CyclinB | CDK1/cycB | CDK1/cyc A | CDK | B-cell |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Cell Cycle Compound Library | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1258.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-16 | |
| $147.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-24 | |
| $147.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY